Faegre Drinker Biddle & Reath LLP, a Delaware limited liability partnership | This website contains attorney advertising.

Biosciences & Public Health

Overview

From manufactures and pharmacies to the patients who benefit from the delivery of care, Faegre Drinker's biosciences and public health team partners with clients to develop and deliver medicine, treatment, and patient access to care across the public health spectrum. Our highly experienced and interdisciplinary team of attorneys, medical doctors, PhDs, and senior public health leaders combines 50+ years of legal, government relations, science, and research experience to develop and implement policy solutions that support patient access to care. Our clients include nonprofit organizations, patient communities, patient-focused drug development companies, patient advocacy organizations, pharmaceutical companies and manufactures, pharmacies, digital health technology, and telehealth companies.

Faegre Drinker Consulting professionals do not act as attorneys for clients. Learn more about the Faegre Drinker Consulting practice.

Insights & Events

Latest

Updates April 2026

FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget

Between a Doorstop and a Starting Gun
121 min read
Updates February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
Updates November 2025

What Does the Agreement to Reopen the Federal Government Mean for Health Policy Interests?

And What Opportunities May Lie Ahead?
5 min read
Media Mentions October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read
Published Articles October 2025

'Most-Favored Nation' Drug Pricing: Impacts on the Pharmacy Supply Chain

National Association of Boards of Pharmacy’s Innovations
1 min read
Media Mentions September 2025

Megan Herber Discusses Health Care Price Transparency Policy With Oncology Practices

Oncology News Central
1 min read
Speaking Engagement Recap May 20, 2025

Health Policy in a New Administration: What Has Changed and What it Means For Individuals, Nonprofits and Corporations

1 min read
Press Release May 2025

Faegre Drinker Grows Life Sciences Consulting Team With Nationally Recognized Patient Experience Researcher Holly Peay, PhD

2 min read
Speaking Engagement Recap January 31, 2025

8th Annual Wow! or Yeow!? 2025: FDA 2024 in Review - Webinar

1 min read
Press Release February 2023

Faegre Drinker Elevates 6 Consulting Professionals to Principal

3 min read
Insights
Updates April 2026

FDA-Related Legislative and Regulatory Proposals and Funding Change the President's FY27 Budget

Between a Doorstop and a Starting Gun
121 min read
Updates February 2026

FDA Publishes Long-Awaited Draft Guidance on “Plausible Mechanism Framework” to Spur the Development of New Individualized Medicines

Anticipated Deadline for Comments Is April 27, 2026
7 min read
Updates November 2025

What Does the Agreement to Reopen the Federal Government Mean for Health Policy Interests?

And What Opportunities May Lie Ahead?
5 min read
Media Mentions October 2025

Libby Baney Comments on Uncertainty in Prescription Drug Market With the Washington Post

1 min read
Published Articles October 2025

'Most-Favored Nation' Drug Pricing: Impacts on the Pharmacy Supply Chain

National Association of Boards of Pharmacy’s Innovations
1 min read
Media Mentions September 2025

Megan Herber Discusses Health Care Price Transparency Policy With Oncology Practices

Oncology News Central
1 min read
Media Mentions May 2025

Nisha Quasba Comments on Drug Importation From Canada in Law360

1 min read
Media Mentions May 2025

Nisha Quasba Discusses Trump’s Push to Boost Drug Imports in Bloomberg Law

1 min read
Published Articles April 2025

Accuracy of Medicare Information Provided by State Health Insurance Assistance Programs

1 min read
Published Articles March 2025

Breaking the Silence: Challenges and Opportunities in Pediatric Drug Development

1 min read